Our role in moulding the image of cancer
The mass media and high-profile cancer campaigns have a major influence in shaping public perceptions of cancer. But who can influence the media? Download full article
January 2011
Klaus Meier: together we can offer the best of both worlds
As more cancers are treated as chronic diseases, and cancer regimens become more complex, difficulties with adherence and the potential for damaging interactions are steadily rising. Download full article
Management of metastatic pancreatic cancer: current strategies and future directions
Despite recent progress, pancreatic cancer remains one of the worst cancer diagnoses. Malcolm Moore reviews current management and considers future progress. Download full article
Promoting genetic literacy: cancer control in the BRCA era
As more is learned about inherited genetic mutations that make cancers more likely, there is an acute need to give those who live with the mutated genes clear information and accurate advice. Download full article
Desperately seeking a bone marrow match
A powerful media campaign that wiil transform the prospects of Romanian patients in need of transplant treatments won TV journalist Paula Herlo an ESO BCRA. Download full article
Real compassion is about moving things forward
The decision to focus on infections associated with cancer treatments, back in the early ’70s, put Jean Klastersky on a path that would lead to him pioneering the field of supportive care in cancer. Download [more]
Gemcitabine alone or plus cisplatin for biliary tract cancer?
A randomised phase III trial comparing cisplatin plus gemcitabine with gemcitabine alone for patients with advanced biliary tract cancer has provided evidence for a new standard treatment option for these patients. The therapeutic outcome (overall [more]
Molecular selection for smart’ study design in lung cancer
The ZODIAC trial reported that the addition of vandetanib to docetaxel in second-line treatment of unselected patients with metastatic non-small-cell lung cancer resulted in a statistically significant improvement in progression-free survival compared with docetaxel alone. [more]
NEWSROUND
Selected Reports by Janet Fricker Download full article